Yong Zeng,
Associate Professor,
University of Florida
Dr. Zeng is an associate professor of chemistry and affiliate faculty of Biomedical Engineering at the University of Florida, and a member of UF Health Cancer Center. He obtained his PhD in Chemistry from University of Alberta, Canada and completed the postdoc training at University of California, Berkeley. Dr. Zeng’s research draws on chemistry, nanomaterials, bioengineering, and medicine to develop innovative micro and nanoscale tools to advance precision medicine of cancer. His technology innovations span from biomolecular assays to micro/nano systems for sensitive measurements of liquid biopsies and molecular biomarkers. His group is also devoted to translational research to bring the technological innovations to clinical sciences, closely collaborating with biologists and clinicians. Dr. Zeng is internationally recognized for his pioneering research in developing microfluidic technologies for isolation and analysis of tumor-derived extracellular vesicles (EVs) for cancer diagnostics and therapeutics. His research programs have been continuously funded by NIH and other funding agencies and led to many highly visible publications on top-tier journals, including Nat. Biomed. Eng. and Sci. Transl. Med., which were featured in public media outlets such as the NIH Director’s Blog and the JAMA Network.
Enabling Microfluidics and Nanosensing Technologies for Circulating Biomarker Analysis
Tuesday, 27 September 2016 at 14:00
Add to Calendar ▼2016-09-27 14:00:002016-09-27 15:00:00Europe/LondonEnabling Microfluidics and Nanosensing Technologies for Circulating Biomarker AnalysisNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Developing circulating biomarkers and blood-based tests is extremely appealing for non-invasive cancer diagnosis and monitoring of therapy response where tissue biopsy is highly invasive and costly. However, in many case circulating biomarkers (e.g., ctDNA, proteins and exosomes) are present at very low concentration levels. In comparison with nucleic acids that can be amplified, quantitative detection of low-level proteins and extracellular vesicles remains very challenging. We have been developing new nanotechnology and microfluidics-based sensing platforms for ultrasensitive analysis of circulating biomarkers with broad dynamic range. These technologies substantially enhances the analytical performance, while reducing the sample demand and analysis time. We will demonstrate the applications of these microfluidic platforms to quantitative analysis of protein biomarkers and tumor-derived exosomes in circulation as a means for liquid biopsy based non-invasive diagnosis of cancer diagnostics. Overall, these microfluidic systems would provide enabling bioanalytical technologies to promote quantitative measurement of complex biological systems and clinical disease diagnosis.
Add to Calendar ▼2016-09-26 00:00:002016-09-28 00:00:00Europe/LondonNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016NGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-27 14:00:002016-09-27 15:00:00Europe/LondonEnabling Microfluidics and Nanosensing Technologies for Circulating Biomarker AnalysisNGS, SCA, SMA and Mass Spec: Research to Diagnostics 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
